Psilocybin Brain Stimulation and Imaging Pilot Study (OPTE)

This open-label Phase I trial (n=15) will investigate the effects of psilocybin (25mg) on brain function and cognitive control in healthy adults, using electroencephalogram (EEG) and transcranial magnetic stimulation (TMS).

Conducted by Johns Hopkins University, this study aims to explore how psilocybin influences brain activity, particularly inhibitory responses measured through EEG during TMS. Participants will be adults aged 22–55 with prior experience using hallucinogens, but without recent use or psychiatric conditions. Researchers will measure changes in specific brain wave patterns and subjective experiences using the Mystical Experience Questionnaire (MEQ30). The study is expected to run from March 2025 to August 2026.

Topic Healthy Subjects Neuroscience
Compound Psilocybin
Country United States of America
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Johns Hopkins University
Johns Hopkins University (Medicine) is host to the Center for Psychedelic and Consciousness Research, which is one of the leading research institutes into psychedelics. The center is led by Roland Griffiths and Matthew Johnson.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.